Canaccord Genuity Reiterates a 'Buy' Rating on Medifast (MED); Inexpensive Growth to Stuff in Your Stockings
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' rating on Medifast (NYSE: MED), PT $40.
Canaccord analyst says, "We reiterate our thesis that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "We reiterate our thesis that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
